Biotech Leadership & Growth: Elucid named Mark Miller as Chief Revenue Officer to push commercial expansion ahead of its cardiovascular platform launch, pairing FDA-cleared Plaque-IQ with BioIntegrated FFR-CT pending clearance. Women’s Health FDA Milestone: Rejoni won FDA approval for the Juveena Hydrogel System to reduce intrauterine adhesions after hysteroscopic adhesiolysis, targeting a recurring, procedure-heavy condition. Oncology Trial Progress: Corbus reported first patient dosed in its TEMPO-1 registrational study of CRB-701 for 2L+ oropharyngeal cancer, while Veracyte highlighted Decipher Prostate results suggesting hormone therapy benefit for higher-risk patients. Rare Disease Pipeline: Tectonic Therapeutic posted favorable Phase 1a topline safety for TX2100 in hereditary hemorrhagic telangiectasia and said the FDA granted Fast Track. AI in Housing/Healthcare Ops: EliseAI raised $350M at a $4B valuation to automate workflows across housing and healthcare systems. Public Health/Community: National Shattering Silence Coalition received a $229,337 Bristol Myers Squibb grant to launch Crisis to Care, a family navigation pilot for severe mental illness. Local Tech & City Services: Boston is partnering with Basis Research to use AI to “listen” to rat calls and map infestations, aiming to cut the urban rodent population. Weather & Disruption: A nor’easter battered the East Coast, with flooding and power outages extending into Massachusetts.